FIELD: medicine.
SUBSTANCE: group of inventions relates to oncology, and concerns treatment of melanoma or prostate cancer. To this end, the level of TLR9 is determined and an effective amount of a composition containing naltrexone, naloxone or methylnaltrexone is administered to patients with overexpression of TLR9.
EFFECT: this provides effective treatment of the given group of patients due to the antagonistic effect of naltrexone on TLR9 and thereby reducing the production of inflammatory cytokines.
13 cl, 2 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APTAMERS FOR USE IN INHIBITION AND/OR SUPPRESSION OF TLR9 ACTIVATION | 2017 |
|
RU2789087C2 |
| COVALENTLY CLOSED NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | 2015 |
|
RU2668387C2 |
| USE OF GENETICALLY MODIFIED PATHOGENIC MEASLES VIRUS WITH IMPROVED APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY | 2014 |
|
RU2700083C2 |
| NEW SYNTHETIC TLR9 AGONISTS | 2008 |
|
RU2468819C2 |
| IMMUNOSTIMULATING G,U-CONTAINING OLYGORIBONUCLEOTIDES | 2003 |
|
RU2302865C2 |
| NON-CODING IMMUNOMODULATORY DNA CONSTRUCT | 2011 |
|
RU2583291C2 |
| ANTAGONISTS OF TOL-LIKE RECEPTOR 4 AND USE IN AUTOIMMUNE LIVER DISEASES | 2016 |
|
RU2707560C2 |
| ASSAY FOR MEASURING CELL-MEDIATED IMMUNORESPONSIVENESS | 2010 |
|
RU2605381C2 |
| ANTI-TUMOR EFFECTS OF A VIRAL VECTOR ENCODING A TOLL-LIKE RECEPTOR AND A TOLL-LIKE RECEPTOR AGONIST | 2017 |
|
RU2741228C2 |
| IMMUNOGENIC COMPOSITION, VACCINE COMPRISING SAME, KIT FOR PREPARING SAID COMPOSITION AND METHOD OF TREATING DISEASES ASSOCIATED WITH GASTRIN SECRETION PATHOLOGY | 2014 |
|
RU2664197C2 |
